Research graph
References from A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients. Local targets link to admitted publications; unresolved targets remain external evidence.
Triple-negative breast cancer: clinical features and patterns of recurrence
10.1158/1078-0432.ccr-06-3045 · 2007 · External reference
Advances in ovarian cancer therapy
10.1007/s00280-017-3501-8 · 2018 · External reference
Strategies and challenges for the next generation of antibody-drug conjugates
10.1038/nrd.2016.268 · 2017 · External reference
Antibody-drug conjugates for cancer treatment
10.1146/annurev-med-061516-121357 · 2018 · External reference
Antibody-drug conjugates (ADCs): current and future biopharmaceuticals
10.1186/s13045-025-01704-3 · 2025 · External reference
Mirvetuximab soravtansine in FRα-Positive, platinum-resistant ovarian cancer
10.1056/nejmoa2309169 · 2023 · External reference
Sacituzumab Govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · 2021 · External reference
Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer
10.1056/nejmoa1814213 · 2019 · External reference
Parallel genomic alterations of antigen and payload targets mediate Polyclonal acquired clinical resistance to Sacituzumab Govitecan in triple-negative breast cancer
10.1158/2159-8290.cd-21-0702 · 2021 · External reference
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER study
10.1186/s13046-020-01797-3 · 2020 · External reference
Development of an FRα companion diagnostic immunohistochemical assay for Mirvetuximab Soravtansine
10.5858/arpa.2023-0149-oa · 2024 · External reference
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
10.1038/s41698-021-00165-4 · 2021 · External reference
Patient selection strategies to maximize therapeutic index of antibody-drug conjugates: prior approaches and future directions
10.1158/1535-7163.mct-19-0993 · 2020 · External reference
FDA approval summary: mirvetuximab soravtansine-gynx for FRα-Positive, platinum-resistant ovarian cancer
10.1158/1078-0432.ccr-23-0991 · 2023 · External reference
Efficacy and safety of Mirvetuximab Soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study
10.1200/jco.22.01900 · 2023 · External reference
Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer
10.1056/nejmoa2407086 · 2024 · External reference
Mirvetuximab soravtansine in platinum-resistant ovarian cancer
10.1177/11795549231187264 · 2023 · External reference
Efficacy and safety of Anti-Trop-2 antibody drug Conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer
10.1200/jco.2016.70.8297 · 2017 · External reference
Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study
10.1200/jco.2025.43.17_suppl.lba109 · 2025 · External reference
Challenges in circulating tumour cell research
10.1038/nrc3820 · 2014 · External reference
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
10.1056/nejmoa040766 · 2004 · External reference
The role of liquid biopsy in epithelial ovarian cancer: state of the art
10.1016/j.critrevonc.2024.104263 · 2024 · External reference
Circulating tumour cells are a prognostic indicator in advanced high-grade serous ovarian cancer and are associated with platelets and immune cells following dissemination
10.1038/s41416-025-03227-7 · 2026 · External reference
Unveiling the impact of circulating tumor cells: two decades of discovery and clinical advancements in solid tumors
10.1016/j.critrevonc.2024.104483 · 2024 · External reference
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition
10.1126/science.1228522 · 2013 · External reference
Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancer
10.1186/s12935-025-04036-x · 2025 · External reference
Efficacy of lapatinib in patients with HER2-Negative metastatic breast cancer and HER2-Positive circulating tumor cells-the DETECT III clinical trial
10.1093/clinchem/hvad144 · 2024 · External reference
Isolation of circulating tumor cells from multiple epithelial cancers with ApoStream(®) for detecting (or monitoring) the expression of folate receptor Alpha
10.4137/bmi.s35075 · 2016 · External reference
Detection of folate receptor-positive circulating tumor cells as a biomarker for diagnosis, prognostication, and therapeutic monitoring in breast cancer
10.1002/jcla.24180 · 2022 · External reference
Efficient detection of heterogeneous CTCs using folate modified magnetic beads combined with microfluidic spatial confinement signal amplification
10.1016/j.ces.2025.121983 · 2025 · External reference
TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs
2024 · External reference
Pembrolizumab for early triple-negative breast cancer
10.1056/nejmoa1910549 · 2020 · External reference
756P first-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
10.1016/j.annonc.2023.09.1935 · 2023 · External reference
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
10.1038/s41591-023-02612-0 · 2023 · External reference
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer
10.1007/s10637-020-00995-2 · 2021 · External reference
PD-L1 expression in triple-negative breast cancer
10.1158/2326-6066.cir-13-0127 · 2014 · External reference
Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells
10.1073/pnas.2601563123 · 2026 · External reference
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
10.1186/s13058-019-1215-z · 2019 · External reference
Role of the International Society of Liquid Biopsy (ISLB) in establishing quality control frameworks for clinical integration
10.1016/j.critrevonc.2025.104619 · 2025 · External reference
